Key Takeaways
- Inhealthcare and FibriCheck expand their partnership to provide hospital-grade heart monitoring via NHS virtual ward pathways.
- The integration aims to enhance cardiac care, reduce NHS spending, and improve patient access to heart health management.
- FibriCheck offers high accuracy in arrhythmia detection, significantly outperforming consumer wearables.
Transforming Cardiac Care in the NHS
Digital health companies Inhealthcare and FibriCheck have advanced their partnership to enhance cardiovascular care by bringing hospital-grade heart monitoring into patients’ homes through NHS virtual ward pathways. Initially announced in September 2023, this collaboration lets clinicians access FibriCheck’s heart monitoring data easily through Inhealthcare’s platform, streamlining the care process within existing NHS systems.
Bryn Sage, Inhealthcare’s CEO, highlighted the integration of their virtual ward expertise with FibriCheck’s proven monitoring capabilities. This collaboration aims at tackling the growing pressures on healthcare systems, particularly because cardiovascular diseases currently affect about seven million people in the UK, costing the NHS approximately £7.4 billion annually.
The partnership’s primary step includes working with NHS Scotland to incorporate FibriCheck into the Connect-Me pathways. These pathways facilitate effective communication between patients and healthcare professionals in Scotland.
Lars Grieten, CEO of FibriCheck, noted that this partnership marks a crucial advancement in cardiac care. The integration of smartphone-based heart monitoring technology allows clinicians to provide high-quality, cost-effective care by utilizing devices that patients already own. This not only improves access to care but also encourages patients to proactively manage their heart health, enabling the NHS to detect and treat cardiovascular conditions earlier while optimizing healthcare resources.
FibriCheck provides longitudinal data on heart rhythm and heart rate measurements, allowing users to log symptoms alongside each measurement. This adds significant context to the data, aiding clinical decision-making with symptom-rhythm insights. According to clinical research, FibriCheck boasts an overall accuracy of 97%, significantly outperforming consumer wearables in detecting atrial arrhythmias compared to traditional methods.
Inhealthcare has developed over 150 clinically designed digital health services, which have been utilized by four million patients across the UK. It supports more than 50 NHS trusts in England, five health and social care trusts in Northern Ireland, and has a national agreement with NHS National Services Scotland for service delivery across 12 health boards. Recently, in December 2023, Inhealthcare secured an NHS contract to expand virtual wards in Calderdale, Kirklees, Leeds, and Wakefield, aiming to enhance care delivery outside traditional hospital settings.
Additionally, researchers at Imperial College Healthcare NHS Trust are exploring advancements in detecting heart disease risk among female patients using AI. A study funded by the British Heart Foundation, published in Lancet Digital Health in March 2025, indicated that women whose electrocardiograms more closely resemble typical male patterns tend to present larger heart chambers and increased muscle mass, highlighting the necessity for tailored approaches in cardiac care by gender.
This collaboration between Inhealthcare and FibriCheck signifies a promising shift towards more accessible, efficient, and patient-empowered cardiovascular healthcare in the UK.
The content above is a summary. For more details, see the source article.
